ERBB2 and neoplasm: The acquisition of more aggressive molecular subtypes in the metastatic setting, such as HER2‐enriched and basal‐like [34], especially in HR+/HER2‐negative disease, may be due to patient selection, changes in the tumor biology due to its inherent evolution, the effects of therapies, or a combination of all.